Related Experiment Videos
Pharmacological issues relating to viral resistance
1Dept. of Pharmacology and Therapeutics, University of Liverpool, UK.
Infection
|July 8, 2000
Summary
Drug resistance is a key factor in anti-HIV treatment failure. This review examines how nucleoside reverse transcriptase inhibitors and protease inhibitors can become less effective due to cellular mechanisms.
Area of Science:
- Pharmacology
- Virology
- Molecular Biology
Background:
- Anti-HIV drug regimens can fail due to virological resistance, adherence issues, and poor tolerability.
- Pharmacological resistance is a critical factor contributing to treatment failure in HIV therapy.
Purpose of the Study:
- To review the development of pharmacological resistance in anti-HIV drug regimens.
- To highlight mechanisms of resistance for nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors.
Main Methods:
- Literature review focusing on pharmacological resistance mechanisms.
- Analysis of cellular processes affecting drug efficacy.
Main Results:
- Nucleoside reverse transcriptase inhibitors (NRTIs) may face resistance through down-regulation of intracellular phosphorylation.
- Protease inhibitors can be affected by efflux transporters like p-glycoprotein (p-gp) and multi-drug resistance proteins (MRPs), reducing intracellular drug concentrations.
Conclusions:
- Pharmacological resistance, driven by intracellular phosphorylation changes and drug efflux transporters, significantly impacts the effectiveness of anti-HIV medications.
- Understanding these mechanisms is crucial for overcoming treatment failures and optimizing HIV therapy.